FIELD: biotechnology.
SUBSTANCE: invention relates to an antibody or its antigen-binding fragment that binds to GPRC5D, compositions containing it and a method for obtaining it, as well as to an isolated polynucleotide encoding it, a vector and a cell containing the above polynucleotide. Also a bispecific antigen-binding molecule that specifically binds to GPRC5D and CD3, a composition containing it and a method of obtaining it, as well as an isolated polynucleotide encoding it, a vector and a cell containing the above polynucleotide are disclosed.
EFFECT: invention is effective for the treatment of multiple myeloma.
37 cl, 15 dwg, 13 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| POLYPEPTIDE LINKER FOR PRODUCTION OF MULTI-SPECIFIC ANTIBODIES | 2018 |
|
RU2776302C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| ANTIBODIES BINDING TO HLA-A2/WT1 | 2018 |
|
RU2815176C2 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
| BISPECIFIC ANTIBODIES SPECIFIC RELATIVELY TO COSTIMULATORY TNF-RECEPTOR | 2016 |
|
RU2761115C1 |
